***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: Two trials of moderate quality in children (n = 134) with no evidence of airflow restriction did not find any benefits from oral beta2-agonists. Five trials in adults (n = 418) had mixed results but overall summary statistics did not reveal any significant benefits from oral (three trials) nor from inhaled (two trials) beta2-agonists. Three studies with low-quality evidence demonstrated no significant differences in daily cough scores, nor in the percentage of adults still coughing after seven days (control group 71%; risk ratio (RR) 0.86, 95% confidence interval (CI) 0.63 to 1.18; 220 participants). In one trial, subgroups with evidence of airflow limitation had lower symptom scores if given beta2-agonists. The trials that noted quicker resolution of cough with beta2-agonists were those with a higher proportion of people wheezing at baseline. Low-quality evidence suggests that adults given beta2-agonists were more likely to report tremor, shakiness or nervousness (RR 7.94, 95% CI 1.17 to 53.94; 211 participants; number needed to treat for an additional harmful outcome (NNTH) 2). There is no evidence to support the use of beta2-agonists in children with acute cough who do not have evidence of airflow restriction. There is also little evidence that the routine use of beta2-agonists is helpful for adults with acute cough. These agents may reduce symptoms, including cough, in people with evidence of airflow restriction. However, this potential benefit is not well supported by the available data and must be weighed against the adverse effects associated with their use.
Output:

Our searches are current to May 2015. We found no new trials. In previous searches, we found seven randomised controlled trials that used beta2-agonist drugs for people with acute bronchitis. Two trials studied children aged one to 10 years (134 participants) and five were conducted in adults (418 participants). None of the studies reported receiving grants from drug-making companies to conduct the study, but people who work for a drug maker were listed as authors on reports from two trials and study drugs were supplied free of charge by the company in three trials. Daily cough scores were no different between children given oral beta2-agonists and children in the placebo control groups. Daily cough scores, or the number of people still coughing after seven days, did not change in the adult trials either. However, the results were mixed. Some trials show a benefit and some show no benefit. This may be because some participants also had wheezing or other signs of narrowed airways, in which case beta2-agonists may be helpful only for them. More of the adults taking beta2-agonists had tremor, shakiness or nervousness. We rated this as low or moderate. There were few trials, with small numbers of people with acute bronchitis or cough. The trials were of short duration (three to seven days) and only two used inhaled beta2-agonists, which is now the usual way the drug is taken by adults and older children. Some important information about how the trial was done was not mentioned in the papers giving results for many of the trials.